Research

Hormonal

SGLT2 inhibitors reduce cardiovascular risk (specifically heart failure) independently of, or partially mediated by, the modest weight loss achieved.

SGLT2 inhibitors are prescribed for diabetes, but they also significantly lower the risk of heart failure. This benefit is linked to the modest weight loss and metabolic changes the drug causes. Even if your blood sugar control doesn't change drastically, your heart health may improve.

StrongSupportsVERY_HIGH confidence
A recent systematic review and meta-analysis of large CVOTs with different glucose-lowering drugs showed a significant relative reduction in the risk of heart failure of 5.9% (3.9–8.0%) for every difference of 1 kg between treatment groups... Another meta-analysis with meta-regression concluded that GLP-1 RAs and SGLT2is reduce the risk of cardiovascular and mortality endpoints regardless of the reductions in systolic blood pressure and body weight.
Andrej Janež et al. · Diabetes Therapy · 2021

Why this rating

Based on large-scale Cardiovascular Outcome Trials (CVOTs) and meta-analyses.

Source

SGLT2 Inhibitors and the Clinical Implications of Associated Weight Loss in Type 2 Diabetes: A Narrative Review

Andrej Janež et al. · Diabetes Therapy · 2021

DOI 10.1007/s13300-021-01104-z

narrative_reviewCited 52×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →